Drug intelligence / Profile preview

ALPHA-5

Development stage: Preclinical
Lead developer: Pasithea Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

ALPHA-5 is a preclinical-stage monoclonal antibody developed by Pasithea Therapeutics. It targets alpha-5 beta-1 integrin and is being investigated for the treatment of amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and other neuroinflammatory disorders. Pasithea Therapeutics acquired the asset, which was originally developed by Alpha-5 integrin, with the aim of filing an Investigational New Drug (IND) application by the end of 2023.

Targets

ITGA5:ITGB1 (Integrin α5β1)

Beyond the preview

Go deeper on ALPHA-5.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALPHA-5.

Explore the full profile